Q-omics provides the consensus-scored VPS13A profile across patient tissues and cancer cell-line models. VPS13A expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, VPS13A is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, VPS13A RNA expression shows 21,570 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where VPS13A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VPS13A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VPS13A survival associations across molecular data types. VPS13A RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VPS13A RNA expression–survival associations across cancer types. High VPS13A expression shows unfavorable associations in ACC, LIHC and MESO, but favorable associations in KIRC, READ and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for VPS13A RNA expression.
This table summarizes VPS13A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for VPS13A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VPS13A shows lower tumor expression in THCA, BRCA, KICH and UCEC and higher tumor expression in LIHC and CHOL. The THCA box plot shows higher VPS13A RNA expression in normal versus tumor tissue (log2 FC = −0.675, t-test p < 0.001).
This table shows molecular features associated with VPS13A in patient tissues and cancer cell lines. In patient samples, VPS13A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, VPS13A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
